{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:09:52Z","timestamp":1753891792700,"version":"3.41.2"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T00:00:00Z","timestamp":1555372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00283","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T05:30:15Z","timestamp":1555392615000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Locally Advanced Non Small Cell Lung Cancer: The Case for Radiation Dose De-escalation in the Management of the Mediastinum"],"prefix":"10.3389","volume":"9","author":[{"given":"Viacheslav","family":"Soyfer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin W.","family":"Corn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1002\/1097-0142(19800601)45:11<2744::AID-CNCR2820451108>3.0.CO;2-U","article-title":"A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group","volume":"45","author":"Perez","year":"1980","journal-title":"Cancer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","article-title":"Standard-dose versus high-dose conformal radiotherapy with concurrent consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small cell lung cancer (RTOG 06-17): a randomized two-by-two factorial phase III study","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial","volume":"35","author":"Chun","year":"2017","journal-title":"J Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1200\/JCO.2016.70.0229","article-title":"Cardiac toxicity after radiotherapy for stage III Non\u2013Small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy","volume":"35","author":"Wang","year":"2017","journal-title":"J Clin Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ijrobp.2011.11.069","article-title":"RTOG protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung","volume":"84","author":"Suntharalingam","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.jtho.2017.06.007","article-title":"Randomized phase II study of preoperative chemoradiotherapy \u00b1 panitumumab followed by consolidation chemotherapy in potentially operable locally advanced (Stage IIIa, N2+) non-small cell ling cancer: NRG oncology RTOG 0839","volume":"12","author":"Edelman","year":"2017","journal-title":"J Thorac Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ijrobp.2013.07.029","article-title":"Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis","volume":"87","author":"Palma","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B8","doi-asserted-by":"publisher","first-page":"E35","DOI":"10.1016\/j.ijrobp.2018.02.125","article-title":"Radiation-induced immunosuppression in locally advanced non-small-cell lung cancer: another cardiac toxicity?","volume":"101","author":"Contreras","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ijrobp.2018.07.188","article-title":"Concurrent daily cisplatin and high-dose radiotherapy in patients with stage III non-small-cell lung cancer","volume":"102","author":"Dieleman","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/0284186X.2017.1293288","article-title":"Is there a different dose-effect relation between the primary tumor and involved lymph nodes in locally advanced non-small-cell lung cancer? A hypothesis-generating study","volume":"56","author":"Van den Bosch","year":"2017","journal-title":"Acta Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3109\/0284186X.2013.868035","article-title":"Pattern of locoregional failure after definitive radiotherapy for NSCLC","volume":"53","author":"Schytte","year":"2014","journal-title":"Acta Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.ijrobp.2015.01.036","article-title":"Differences between colon cancer primaries and metastases using a molecular assay for tumor radiation sensitivity suggest implications for potential oligometastatic SBRT patient selection","volume":"92","author":"Ahmed","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B13","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/annonc\/mdw051","article-title":"Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer","volume":"27","author":"Villaflor","year":"2016","journal-title":"Ann Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemo-radiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with Durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S1470-2045(16)30648-9","article-title":"A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study","volume":"18","author":"Scott","year":"2017","journal-title":"Lancet Oncol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00283\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T05:30:17Z","timestamp":1555392617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00283\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,16]]},"references-count":16,"alternative-id":["10.3389\/fonc.2019.00283"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00283","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2019,4,16]]},"article-number":"283"}}